Threshold Pharmaceuticals Announces Presentation and Webcast at the 12th Annual Needham Healthcare Conference

Threshold Pharmaceuticals Announces Presentation and Webcast at the 12th Annual 
Needham Healthcare Conference 
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/25/13 --  Threshold
Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry
Selick, Ph.D., Threshold's Chief Executive Officer, will present a
company overview at the 12th Annual Needham Healthcare Conference on
April 30, 2013, at 1:40 p.m. ET. 
A live webcast of the presentation will be available under Webcasts
in the Investors section of www.thresholdpharm.com. A replay of the
presentations will be archived on the site for 30 days. 
About Threshold Pharmaceuticals 
 Threshold Pharmaceuticals, Inc. is
a biotechnology company focused on the discovery and development of
drugs targeting tumor hypoxia, the low oxygen condition found in the
microenvironments of most solid tumors as well as the bone marrows of
some patients with hematologic malignancies. This approach offers
broad potential to treat a variety of cancers. By selectively
targeting tumor cells, we are building a pipeline of drugs that hold
promise to be more effective and less toxic to healthy tissues than
conventional anticancer drugs. For additional information, please
visit our website (www.thresholdpharm.com). 
Forward-Looking Statements
 Except for statements of historical fact,
the statements in this press release are forward-looking statements,
including statements regarding the potential therapeutic uses and
benefits of its product candidates. These statements involve risks
and uncertainties that can cause actual results to differ materially
from those in such forward-looking statements. Potential risks and
uncertainties include, but are not limited to, Threshold's ability to
enroll or complete its anticipated clinical trials, the time and
expense required to conduct such clinical trials and analyze data,
issues arising in the regulatory or manufacturing process and the
results of such clinical trials (including product safety issues and
efficacy results). Further information regarding these and other
risks is included under the heading "Risk Factors" in Threshold's
Annual Report on Form 10-K, which has been filed with the Securities
and Exchange Commission on March 7, 2013 and is available from the
SEC's website (www.sec.gov) and on our website
(www.thresholdpharm.com) under the heading "Investors." We undertake
no duty to update any forward-looking statement made in this news
release. 
Contact 
Laura Hansen, Ph.D.
Senior Director, Corporate Communications
Threshold Pharmaceuticals
Phone: 650-474-8206
E-mail: lhansen@thresholdpharm.com 
 
 
Press spacebar to pause and continue. Press esc to stop.